Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 17.50% is 71% above its 5-year average of 10.21%, near the high end of its 5-year range (0.20%–17.50%).
As of the fiscal period ended Tuesday, June 30, 2026. 23.99% above its 12-month average of 14.12%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 17.50%.
DEBT TO ASSETS RATIO
17.50%
DEBT TO ASSETS RATIO AVG TTM
14.12%
DEBT TO ASSETS RATIO AVG 3Y
10.89%
DEBT TO ASSETS RATIO AVG 5Y
10.21%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+23.99%
CURRENT VS 3Y AVG
+60.73%
CURRENT VS 5Y AVG
+71.44%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+19348.18%
vs the sector median at left
Zentalis Pharmaceuticals, Inc.
Market Cap
$192.92M
Debt to Assets Ratio
17.50%
TTM Avg
14.12%
3Y Avg
10.89%
5Y Avg
10.21%
Market Cap
$189.50M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$184.32M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$184.22M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$182.79M
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | $192.92M | 17.50% | 14.12% | 10.89% | 10.21% |
| RxSight, Inc. (RXST)vs › | $192.29M | 0.03% | N/A | N/A | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $189.50M | 0.00% | N/A | N/A | N/A |
| Surrozen, Inc. (SRZN)vs › | $199.87M | 0.05% | N/A | N/A | N/A |
| Alector, Inc. (ALEC)vs › | $200.40M | 0.16% | N/A | N/A | N/A |
| Exagen Inc. (XGN)vs › | $202.11M | 0.49% | N/A | N/A | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $184.32M | 0.00% | N/A | N/A | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $184.22M | 0.00% | N/A | N/A | N/A |
| Compass Therapeutics, Inc. (CMPX)vs › | $182.79M | 0.05% | N/A | N/A | N/A |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $204.35M | 0.20% | N/A | N/A | N/A |
Debt/Assets
17.5%
Debt/Equity
0.26
Current Ratio
4.82
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 17.50% |
| 2026-03-31 | 15.27% |
| 2025-12-31 | 13.70% |
| 2025-09-30 | 12.36% |
| 2025-06-30 | 11.75% |
| 2025-03-31 | 10.98% |
| 2024-12-31 | 9.91% |
| 2024-09-30 | 9.60% |
| 2024-06-30 | 8.95% |
| 2024-03-31 | 8.14% |
| 2023-12-31 | 8.14% |
| 2023-09-30 | 7.80% |
| 2023-06-30 | 7.46% |
| 2023-03-31 | 9.61% |
| 2022-12-31 | 8.55% |
| 2022-09-30 | 0.42% |
| 2022-06-30 | 0.31% |
| 2022-03-31 | 11.40% |
| 2021-12-31 | 9.73% |
| 2021-09-30 | 0.20% |
| 2021-06-30 | 0.28% |
| 2021-03-31 | 0.33% |
| 2020-12-31 | 0.55% |
| 2020-09-30 | 0.22% |
| 2020-06-30 | 0.31% |
| 2020-03-31 | 178.87% |
| 2019-12-31 | 2.81% |
